Georgetown University

Taletrectinib, a next-gen ROS1 TKI, shows superior efficacy, CNS penetration, and safety in ROS1+ NSCLC, with TRUST-I trial data revealing 90.6% ORR in TKI-naive patients and 51.5% in crizotinib-pretreated. TRUST-II global trial supports consistent activity and safety, with pooled analysis confirming taletrectinib's benefit as a first-line option.

Donald Trump offers expedited governmental approval for $1 billion, bypassing environmental reviews. Critics, including the Sierra Club, oppose this, emphasizing the need for thorough environmental impact assessments.

President-elect Donald Trump plans to expedite approvals for projects with $1B+ investments in the U.S., potentially bypassing environmental laws. The National Environmental Policy Act (NEPA) mandates environmental reviews for federal actions. Trump previously streamlined NEPA during his first term, but Biden reversed these changes. The Supreme Court is currently reviewing NEPA's scope, focusing on upstream and downstream impacts. Corporate groups oppose NEPA's lengthy reviews, while environmental groups argue it protects public health and the climate.

Taletrectinib (AB-106) demonstrated durable responses in ROS1-positive NSCLC patients in the TRUST-II trial, overcoming resistance mutations and reducing off-target AEs compared to other ROS1 TKIs.

Negotiations for FY 2025 appropriations are ongoing, impacting NIH funding; President-elect Trump's nominees for HHS, CMS, CDC, FDA, and Surgeon General spark concern in the medical research community; House Appropriations Subcommittee reviews NIH budget for FY 2025; AACR and FDA host workshops on DPD deficiency and clinical trials; U.S. Surgeon General highlights tobacco use disparities; FDA approves new drugs and updates product labeling.

Shuttle Pharmaceuticals initiates Phase 2 trial of Ropidoxuridine at UVA Cancer Center for glioblastoma treatment, with 40 patients randomized into two doses to determine optimal effectiveness. The trial aims to improve survival rates in IDH wild-type, methylation negative glioblastoma patients, currently treated only with radiation.

Religious beliefs and lack of trust may explain Black patients' hesitancy to join cancer trials, according to a study presented at the American Society for Radiation Oncology Annual Meeting. The study found higher percentages of Black individuals agreed that God determines illness and wellness, and that research harms minorities, compared to non-Black individuals.

Nilotinib, a tyrosine kinase inhibitor, shows promise in treating Dementia with Lewy bodies (DLB) by improving cognitive function and reducing falls, with a favorable safety profile. Presented at the 2024 CTAD conference, a phase 2 trial demonstrated nilotinib's efficacy and safety in DLB patients, with plans for a larger trial.

Polypharmacy, prescribing multiple drugs, leads to adverse drug reactions, ineffective treatments, and high costs. Precision medicine, like pharmacogenomics, tailors treatments to patient genetics, improving outcomes. Team-based care, including medication reviews, deprescribing, patient education, and pharmacist involvement, enhances medication management. The future of healthcare involves personalized, preventative, and effective models.

110+ organizations urge Congress to reauthorize PAHPA by Dec 31, recognizing the opportunity to strengthen national health security during the 2025 leadership transition.